PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

PainReform is committed to developing safe, effective and accessible treatments and therapies for chronic pain syndromes. We strive to apply the latest medical research and technology to create innovative approaches to managing pain.

PainReform seeks to become the preeminent provider of relief from chronic pain, to improve the quality of life for those suffering from its debilitating effects.

PainReform has won numerous awards for its innovative scientific approaches, including the Pharmaceuticals Research and Manufacturers of America's Achievement Award and the National Institute of Health's Dean's Institution Award for Excellence in Pain Research.